CDK4 and neuroendocrine carcinoma: In addition, the CDK4 pathway has been newly mutated in our brain metastasis samples of Clear cell RCCs and not in primary tumor cells, while tumors of neuroendocrine carcinoma, synovial sarcoma and keratinizing SCCs show mutations only in their primaries.